8-K: Pacira BioSciences Unveils Ambitious Five-Year Growth Plan and Reports Preliminary 2024 Revenue

Pacira BioSciences announced a new five-year plan targeting significant growth and a transition into an innovative biopharmaceutical company, alongside preliminary 2024 revenue of $701 million.

Summary

• Pacira BioSciences has announced a five-year plan, called 5x30, aimed at transforming the company into a leading biopharmaceutical organization focused on musculoskeletal pain.
• The company reported preliminary unaudited total revenue of $701.0 million for 2024, an increase from $675.0 million in 2023.
• The 5x30 plan includes objectives to treat over three million patients annually, achieve double-digit compounded annual revenue growth, improve gross margin by five percentage points, expand the clinical pipeline with five novel programs, and establish five strategic partnerships by 2030.
• Fourth quarter net product sales for EXPAREL were $147.7 million in 2024, compared to $143.9 million in 2023.
• Fourth quarter net product sales for ZILRETTA were $33.1 million in 2024, compared to $28.7 million in 2023.
• Fourth quarter net product sales for iovera were $6.5 million in 2024, compared to $6.0 million in 2023.
• Full-year EXPAREL net product sales were $549.0 million in 2024, compared to $538.1 million in 2023, with a 4% average daily volume growth.
• Full-year ZILRETTA net product sales were $118.1 million in 2024, compared to $111.1 million in 2023.
• Full-year iovera net product sales were $22.8 million in 2024, compared to $19.7 million in 2023.
• Other revenue, including sales of bupivacaine liposome injectable suspension and royalties, was $11.1 million in 2024, compared to $6.1 million in 2023.
• The company granted inducement awards to eight new employees, including stock options for 20,300 shares and restricted stock units for 30,400 shares.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with a clear growth strategy and preliminary financial results that show improvement. The ambitious 5x30 plan and focus on innovation suggest a strong future direction for the company.

Positives

• Pacira's 2024 revenue increased to $701.0 million, demonstrating growth compared to the previous year's $675.0 million.
• The company's 5x30 plan outlines clear objectives for significant growth and expansion by 2030.
• EXPAREL, ZILRETTA, and iovera all experienced sales growth in 2024 compared to 2023.
• EXPAREL showed a 4% average daily volume growth for the full year.
• The company is actively expanding its pipeline with five novel programs in development.

Negatives

• Other revenue, including sales of bupivacaine liposome injectable suspension and royalties, was zero in the fourth quarter of 2024, compared to $2.6 million in the fourth quarter of 2023.
• EXPAREL sales were partially offset by a shift in vial mix and discounting due to new GPO partnerships.

Risks

• The financial information provided is preliminary and unaudited, subject to adjustment.
• The company's future performance is subject to various risks, including market acceptance of its products, success of clinical trials, and economic conditions.
• The company's ability to achieve its 5x30 goals is dependent on successful execution of its strategy and management of various risks.
• There are risks associated with acquisitions, manufacturing, supply chain, and global economic conditions.

Future Outlook

Pacira is focused on growth, operational excellence, and delivering innovative non-opioid pain therapies, with a goal to become a therapeutic area leader in musculoskeletal pain and adjacencies. The company aims to achieve its 5x30 plan by 2030, which includes treating over three million patients annually, achieving double-digit compounded annual revenue growth, improving gross margin by five percentage points, expanding the clinical pipeline with five novel programs, and establishing five strategic partnerships.

Management Comments

• Frank D. Lee, chief executive officer of Pacira BioSciences, stated that the company enters 2025 with a sharp focus on growth, operational excellence, and a clear mission to deliver innovative, non-opioid pain therapies.
• Mr. Lee also expressed his excitement to lead Pacira during this new chapter as they advance their 5x30 plan to address unmet patient needs in musculoskeletal pain and adjacencies.
• Management believes that the company is well equipped to extend its leadership in non-opioid pain management and transform Pacira into an innovative biopharmaceutical organization with a robust pipeline to support sustainable growth and enhanced value creation.

Industry Context

This announcement reflects a broader trend in the pharmaceutical industry towards developing non-opioid pain management solutions, driven by the ongoing opioid crisis and the need for safer alternatives. Pacira's focus on musculoskeletal pain aligns with the growing demand for effective treatments in this area.

Comparison to Industry Standards

• Pacira's revenue growth is in line with other companies in the specialty pharmaceutical sector, but the 5x30 plan is more ambitious than many of its peers.
• Companies like Heron Therapeutics and Flexion Therapeutics are also focused on non-opioid pain management, but Pacira's diversified product portfolio and pipeline give it a competitive edge.
• The company's focus on long-acting local analgesics and extended-release intra-articular injections positions it well in the market, as these products offer advantages over traditional pain management methods.
• Pacira's goal of achieving double-digit compounded annual growth is aggressive and will require successful execution of its commercial and development strategies.

Stakeholder Impact

• Shareholders can expect potential long-term value creation through the company's growth plan and pipeline expansion.
• Employees may benefit from the company's growth and expansion, with new opportunities and potential for career advancement.
• Patients will have access to innovative non-opioid pain therapies, improving their quality of life.
• Customers, including healthcare providers, will have access to a broader range of pain management solutions.
• Suppliers and creditors will benefit from the company's continued growth and financial stability.

Next Steps

• Pacira expects to report its complete financial results for the fourth quarter and full-year 2024, along with the company's financial guidance, later in the first quarter of 2025.
• The company will focus on executing its 5x30 plan to achieve its growth objectives by 2030.

Key Dates

Keywords

Pacira BioSciences, EXPAREL, ZILRETTA, iovera, revenue, biopharmaceutical, musculoskeletal pain, non-opioid pain therapies, 5x30 plan, clinical pipeline, partnerships